title: Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators.
abstract: Controlling chronic immunoinflammatory diseases such as lesions in the eye caused by infection with HSV represents a therapeutic challenge. Since CD4(+) T cells are the primary orchestrators of lesions, targeting activated CD4(+) T cell subsets and increasing the representation of cells that express regulatory function would be a logical therapeutic approach. We show that this outcome can be achieved by therapy, systemic or local, with the lectin family member galectin-9. This molecule, which is a natural product of many cell types, acts as a ligand to the inhibitory molecule TIM-3 (T cell Ig and mucin-3) that is expressed by activated but not naive T cells. We show that 50% or more of T cells in ocular lesions caused by HSV in mice express TIM-3 and that blocking signals from its natural ligand with a mAb results in more severe lesions. More importantly, the provision of additional galectin-9, either systemically or more effectively by local subconjuctival administration, diminished the severity of stromal keratitis lesions as well as the extent of corneal neovascularization. Multiple mechanisms were involved in inhibitory effects. These included apoptosis of the orchestrating effector T cells with consequent reduction of proinflammatory cytokines and an increase in the representation of two separate subtypes of regulatory cells as well as inhibitory effects on the production of molecules involved in neovascularization, an essential component of stromal keratitis pathogenesis. Our results indicate that galectin-9 therapy may represent a useful approach to control HSV-induced lesions, the most common cause of infectious blindness in the Western world.
authors.affiliation: Comparative and Experimental Medicine, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN 37996, USA. ss1@utk.edu
authors.forename: Sharvan
authors.initials: S
authors.lastname: Sehrawat
authors.forename: Amol
authors.initials: A
authors.lastname: Suryawanshi
authors.forename: Mitsuomi
authors.initials: M
authors.lastname: Hirashima
authors.forename: Barry T
authors.initials: BT
authors.lastname: Rouse
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000276:immunology; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D016510:Corneal Neovascularization / Q000276:immunology / Q000473:pathology / Q000821:virology; D005260:Female; D037161:Galectins / Q000378:metabolism / Q000502:physiology*; D055879:Gene Knock-In Techniques; D000072597:Hepatitis A Virus Cellular Receptor 2; D018259:Herpesvirus 1, Human / Q000276:immunology*; D016849:Keratitis, Herpetic / Q000276:immunology / Q000473:pathology / Q000821:virology; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D011991:Receptors, Virus / Q000096:biosynthesis / Q000172:deficiency / Q000502:physiology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology; D014709:Vero Cells
chemical_list: D037161:Galectins; C442241:Havcr2 protein, mouse; D000072597:Hepatitis A Virus Cellular Receptor 2; D011991:Receptors, Virus; D042461:Vascular Endothelial Growth Factor A; C508186:galectin 9, mouse